Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/12/2005WO2005032555A3 Pharmaceutical combinations of hydrocodone and naltrexone
05/12/2005WO2005032488A3 2,4-dioxo-3-quinazolinylaryl sulfonylureas
05/12/2005WO2005030131A3 Bis-quinazoline compounds for the treatment of bacterial infections
05/12/2005WO2005027885A3 Composition and method for treating bezoar and trichobezoar
05/12/2005WO2005026083A3 Improved delivery by labile hydrophobic modification of drugs
05/12/2005WO2005025541A3 Dry powder composition comprising a benzodiazepine for pulmonary inhalation
05/12/2005WO2005025536A3 Dry powder composition comprising co-jet milled particles for pulmonary inhalation
05/12/2005WO2005025488A3 Methods for the controlled delivery of pharmacologically active compounds
05/12/2005WO2005023767A3 Diastereomers of 4-aryloxy-3-hydroxypiperidines
05/12/2005WO2005023368B1 Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine
05/12/2005WO2005018644B1 Capped pyrazinoylguanidine sodium channel blockers
05/12/2005WO2005018635A3 Ion channel modulating activity i
05/12/2005WO2005018578A3 Method of treating cancer with hdac inhibitors
05/12/2005WO2005018531A3 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
05/12/2005WO2005016528A3 6-substituted anilino purines as rtk inhibitors
05/12/2005WO2005016514A3 Combinatorial synthesis on support
05/12/2005WO2005013911A3 Protective and therapeutic uses for tocotrienols
05/12/2005WO2005009367A3 Treatment of diseases with kinase inhibitors
05/12/2005WO2005009343A3 A1 adenosine receptor antogonists
05/12/2005WO2005007635A8 Combretastatin derivatives with cytotoxic action
05/12/2005WO2005007072A3 Methods and pharmaceutical compositions for healing wounds
05/12/2005WO2005004836A3 Saquinavir mesylate oral dosage form
05/12/2005WO2005003100A3 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
05/12/2005WO2005002572A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
05/12/2005WO2005000270A3 Inhalable formulations for treating pulmonary hypertension and methods of using same
05/12/2005WO2005000265A3 Gel-stabilized nanoparticulate active agent compositions
05/12/2005WO2005000231A3 Il-8 receptor antagonists
05/12/2005WO2004110375A3 Combination therapy for the treatment of diabetes
05/12/2005WO2004108091A3 Antimicrobial flush solutions
05/12/2005WO2004106297A3 Nonionic surfactant compositions
05/12/2005WO2004105757A3 Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
05/12/2005WO2004105682A3 Carbostyril derivatives and mood stabilizers for treating mood disorders
05/12/2005WO2004104022A3 Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
05/12/2005WO2004103311A3 Antibiotic composition
05/12/2005WO2004101510A3 Polymorphs of cabergoline
05/12/2005WO2004096802A3 ANTIBIOTIC TETRAHYDRO-β-CARBOLINE DERIVATIVES
05/12/2005WO2004091572A3 Cochleate compositions directed against expression of proteins
05/12/2005WO2004089312A3 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
05/12/2005WO2004087061B1 Tubulin binding agents and corresponding prodrug constructs
05/12/2005WO2004084703A3 Temporary embolization using inverse thermosensitive polymers
05/12/2005WO2004082715A8 Concomitant drug as therapeutic agent for inflammatory bowel disease
05/12/2005WO2004080414A3 Composition and method for treating inflammations by reducing c-reactive protein
05/12/2005WO2004073628A3 Novel compounds
05/12/2005WO2004071391A3 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
05/12/2005WO2004064778A3 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/12/2005WO2004044137A3 Modified oligomeric compounds and compositions for use in gene modulation
05/12/2005WO2004039358A8 Adhesive composition for dermal patch and production process thereof
05/12/2005WO2004037162A3 Compositions and methods for the treatment of hepatitis c virus infection
05/12/2005WO2004029281A3 Methods and compositions for rnai mediated inhibition of viral gene expression in mammals
05/12/2005WO2004022775A8 Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use
05/12/2005WO2004017918A8 Method of preparing dry powder inhalation compositions
05/12/2005WO2004009590A8 4-amino-substituted pyrimidine derivatives
05/12/2005WO2004000858A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
05/12/2005WO2003092478A3 Methods for treating neuronal disorders
05/12/2005WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/12/2005WO2001079525A3 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
05/12/2005US20050101955 Spine distraction implant
05/12/2005US20050101804 Reacting a benzophenone compound with a bromine compound in presence of phase transfer catalyst and solvent
05/12/2005US20050101798 C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
05/12/2005US20050101783 N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide
05/12/2005US20050101781 Eponemycin and epoxomicin analogs and uses thereof
05/12/2005US20050101780 Enzyme inhibitors for treatment of cancer leukemia; e.g. bosutinib
05/12/2005US20050101775 Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging
05/12/2005US20050101773 Genes required for viability and/or reproduction in c. elegans and their use in the development of anti-nematode agents
05/12/2005US20050101678 Antibacterial composition
05/12/2005US20050101674 PPMP as a ceramide catabolism inhibitor for cancer treatment
05/12/2005US20050101673 Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas
05/12/2005US20050101672 Dissolving in solvent in which nateglinide is highly soluble such as ethanol, dioxane, dichloromethane, or acetone; adding water or hexane in which nateglinide is not soluble; crystallization
05/12/2005US20050101671 Compounds and compositions for delivering active agents
05/12/2005US20050101668 The use of 5,6-dihydroxy-2-methylaminotetralin (CHF 1035) and/or 5,6-diisobutyroyloxy-2-methylaminotetralin (CHF 1024) as antiischemic agents; cardiovascular disorders
05/12/2005US20050101666 Orally administering escitalopram or its hydrobromide or oxalate salt continuously throughout menstrual cycle intermittently or semi-intermittently
05/12/2005US20050101665 Treatment of neurotic disorders
05/12/2005US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors
05/12/2005US20050101663 Synthetic lactone formulations and method of use
05/12/2005US20050101662 Such as coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7- dihydroxycoumarin (exculetin), 3,6,7 trihydroxycoumarin, warfarin, or warfarin sodium; cancer, Alzheimer's disease, gout, atherosclerosis, restenosis
05/12/2005US20050101661 Cyclooxygenase inhibitors; musculoskeletal and cardiovascular disorders; antiinflammatory agents
05/12/2005US20050101660 Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
05/12/2005US20050101659 by administering the 5-lipoxygenase inhibitor zileuton or a salt thereof
05/12/2005US20050101658 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
05/12/2005US20050101657 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative
05/12/2005US20050101655 Migraine treatments including isovaleramide compounds and serotonin agonists
05/12/2005US20050101654 Process for the preparation of N-amino substituted heterocyclic compounds
05/12/2005US20050101653 Combination therapy for the treatment of migraine
05/12/2005US20050101652 New salt hydrates
05/12/2005US20050101651 Viricides; protease inbhibitors; useful for inhibiting the activity of picornaviral 3C proteases; for example, 6-carbamoyl-4S-{2S-[(5-naphthalen-1-yl-1H-pyrrole-2-carbonyl)-amino-3-phenyl-propionylamino}-hex-2(trans)-enoic acid ethyl ester
05/12/2005US20050101650 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase
05/12/2005US20050101649 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy
05/12/2005US20050101647 For example, 2-(1,3-benzodioxol-5-yl)-6-phenyl-1H-imidazo[4,5-b]pyridinetyrosine; kinase-inhibiting activity; use in treatment of breast cancer, prostate cancer, lung cancer or pancreatic carcinoma
05/12/2005US20050101645 P-(alpha-hydroxyhydrocarbylcarbonylamino)-substituted benzoic acid esters; reducing and/or slowing down the loss of head hair and/or body hair, or inducing and/or stimulating its growth
05/12/2005US20050101644 Benzylether amine compounds useful as CCR-5 antagonists
05/12/2005US20050101642 Niacinamide derivatives as inhibitor of poly(ADP-ribose)polymerase; ranitidine, cimetidine, famotidine, nizatidine as gastric acid secretion control; immunomodulation and suppression of hypersensitivity and inflammatory reaction; IgE mediated allergic reaction; no side effects; virtually non-toxic
05/12/2005US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
05/12/2005US20050101640 Synergistic mixture; hypotensive agents; dosage control
05/12/2005US20050101638 Combination of organic compounds
05/12/2005US20050101637 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
05/12/2005US20050101636 PPAR-activating compound and pharmaceutical composition comprising the compound
05/12/2005US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases
05/12/2005US20050101633 spinal cord injury, spinal cord ischemia-reprefusion injury; P-sulfonamido- or carboxamido phenyl esters of pivalic acid; N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine monosodium salt tetrahydrate; elastase inhibitor; no side effects; inhibited accumulation and infiltration of neutrophil
05/12/2005US20050101632 Treating inflammation of the skin or mucous membrane by topical administration of an anti-inflammatory amount of dimethicone in the absence of any other anti-inflammatory agent
05/12/2005US20050101631 Process for producing carbostyril derivatives
1 ... 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 ... 7860